Study Information
Study Details
View study details on clinicaltrials.gov.
Locations
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
S1900K (LUNG-MAP SUB-STUDY): A Randomized Phase II Study of Tepotinib With or Without Ramucirumab in Participants With MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer
Thistrial is available at multiple Sutter locations. Please contact one of thefollowing about the study:
Site Point of Contacts
Alta Bates (CA164)
Painte’ Berniard Piante.Berniard@sutterhealth.org
California Pacific Medical Center (CA222)
Sophia Vu (Manager) Sophia.Vue@sutterhealth.org
Eden Medical Center (CA200)
Leah Galvez Leah.Galvez@sutterhealth.org
Mills Health Center (CA209)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
Memorial Medical Center (CA182)
Kristen Moorman Kristen.Moorman@sutterhealth.org
Palo Alto Medical Foundation (PAMF – All sites)
Tanya Pozniansky Tanya.Pozniansky@sutterhealth.org
SIMR Sutter Institute for Medical Research (SIMR – All sites)
Kirsten Babski Kirsten.Babski@sutterhealth.org
Sutter Cancer Research Consortium
NCIClinicalTrials@sutterhealth.org
Principal Investigator
Related Studies
The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity
Investigator: Jiang Li, Ph.D., MPH